We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
URS
301
Utah Retirement Systems
Utah
– -$201K -4,300 Closed
Lazard Asset Management
302
Lazard Asset Management
New York
– -$176K -4,123 -99%
PAS
303
Point72 Asia (Singapore)
Singapore
– -$167K -3,587 Closed
QL
304
Quarry LP
New York
– -$117K -2,500 Closed
CFM
305
Catalyst Funds Management
Australia
– -$65.4K -1,400 Closed
AIG
306
American International Group
New York
– -$61.2K -1,311 Closed
Qube Research & Technologies (QRT)
307
Qube Research & Technologies (QRT)
United Kingdom
– -$30K -642 Closed
TC
308
Truvestments Capital
Florida
– -$7.38K -158 Closed
LSA
309
Leonteq Securities AG
Switzerland
– -$5.79K -124 Closed
SS
310
Sunbelt Securities
Texas
– -$4.01K -86 Closed
FPB
311
First PREMIER Bank
South Dakota
– -$2K -53 Closed
ACM
312
Anfield Capital Management
California
– -$1.87K -40 Closed
RAM
313
Riggs Asset Management
Pennsylvania
– -$1.03K -22 Closed
CIBC Private Wealth Group
314
CIBC Private Wealth Group
Georgia
– -$892 -19 Closed
9 10 11 12
13

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.